Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 79-81

  Wootton, Mandy ^a   Walsh, Tim R ^b   Macfarlane, Lorna ^a   Howe, Robin A ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ESBLs; Resistance; Susceptibilities

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; MECILLINAM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENZYME ACTIVITY; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 77950353740     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp404     Document Type: Article

References (13)

1. National Public Health Service for Wales. Antimicrobial Resistance in Wales (2006/2007). Report by the Welsh Antimicrobial Resistance Surveillance Unit. Published November 2007. http://www.wales.nhs.uk/sites3/news.cfm?orgid=457&contentid=15417 (17 September 2009, date last accessed).
2. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.
3. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
4. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62 Suppl 1: 1-9.
5. Zhanel GG, Karlowsky JA, Harding GKM et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother 2000; 44: 1089-92.
6. Naber KG. Survey on antibiotic usage in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 49-52.
7. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46 Suppl 1: 35-9.
8. Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl 2: 73-8.
9. Andrews JM. Determination of Minimum Inhibitory Concentrations.March 2006. BSAC.org/susceptibility_testing/guide_to_antimicrobial_susceptibility_testing.cfm.
10. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO SENS Project. J Antimicrob Chemother 2003; 51: 69-76.
11. Thomas K, Weinbrun MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57: 367-8.
12. Rodriguez-Bano J, Lopez-Cerero L, Navarro MD et al. Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62: 1142-9.
13. Andrews JM. BSAC standardized disc susceptibility testing method (version 7). J Antimicrob Chemother 2008; 62: 256-78.